Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Income (2017 - 2024)

Historic Net Income for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.7 million.

  • Denali Therapeutics' Net Income rose 400.76% to -$114.7 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$114.7 million, marking a year-over-year increase of 7317.27%. This contributed to the annual value of -$422.8 million for FY2024, which is 19111.79% down from last year.
  • Latest data reveals that Denali Therapeutics reported Net Income of -$114.7 million as of Q4 2024, which was up 400.76% from -$107.2 million recorded in Q3 2024.
  • Over the past 5 years, Denali Therapeutics' Net Income peaked at $244.9 million during Q4 2020, and registered a low of -$119.5 million during Q4 2023.
  • Over the past 5 years, Denali Therapeutics' median Net Income value was -$79.9 million (recorded in 2021), while the average stood at -$55.7 million.
  • Its Net Income has fluctuated over the past 5 years, first soared by 55328.09% in 2020, then tumbled by 15399.96% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Net Income stood at $244.9 million in 2020, then crashed by 130.73% to -$75.3 million in 2021, then crashed by 31.11% to -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then increased by 4.01% to -$114.7 million in 2024.
  • Its last three reported values are -$114.7 million in Q4 2024, -$107.2 million for Q3 2024, and -$99.0 million during Q2 2024.